Takeda Pharmaceutical Co Ltd expected to post earnings of JPY87.45 a share - Earnings Preview

Reuters10-29
Takeda Pharmaceutical Co Ltd <tak.n> expected to post earnings of JPY87.45 a share - Earnings Preview </tak.n>
  • Takeda Pharmaceutical Co Ltd TAK.N, TAK is expected to show a rise in quarterly revenue when it reports results on October 31 for the period ending September 30 2024

  • The Chuo-ku Tokyo-to-based company is expected to report a 3.9% increase in revenue to JPY1.084 trillion from JPY1.04 trillion a year ago, according to the mean estimate from 2 analysts, based on LSEG data.

  • ​LSEG's mean analyst estimate for Takeda Pharmaceutical Co Ltd is for earnings of JPY87.45 per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

  • The average consensus recommendation for the pharmaceuticals peer group is also "Buy".​

  • Wall Street's median 12-month price target for Takeda Pharmaceutical Co Ltd is $16.30​, above​ its last closing price of $13.60. ​​​

This summary was machine generated October 29 at 11:21 GMT. All figures in yen unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment